Ask AI
Emerging Agents in HNSCC

CE / CME

Emerging Targeted Therapies for HNSCC: A Focus on EGFR-Directed Bispecific Antibodies

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Pharmacists: 0.25 contact hour (0.025 CEUs)

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

Released: July 28, 2026

Expiration: January 27, 2027

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Deborah J. Wong, MD, PhD, ​discusses the latest therapeutic strategies and targeted treatment options in clinical trials for recurrent and/or metastatic head and neck cancers.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary. 

Before continuing with this educational activity, please take a moment to answer the following questions.

Which of the following was recently reported from the OrigAMI-4 trial evaluating amivantamab monotherapy in patients with R/M HNSCC with progression following immune checkpoint inhibitor + platinum-based chemotherapy?

How many people with HNSCC do you provide care for in a typical month?

For those who practice in academic or community settings, please indicate your practice setting: